PDS Biotechnology (NASDAQ:PDSB) & Forte Biosciences (NASDAQ:FBRX) Head to Head Survey

Forte Biosciences (NASDAQ:FBRX) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Forte Biosciences and PDS Biotechnology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
PDS Biotechnology	N/A	-708.18%	-136.50%

Earnings and Valuation

This table compares Forte Biosciences and PDS Biotechnology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38 million	($4.65)	-16.54
PDS Biotechnology	N/A	N/A	-$34.50 million	($0.64)	-0.33

Forte Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Forte Biosciences and PDS Biotechnology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1	4	1	0	2.00
PDS Biotechnology	1	0	2	0	2.33

Forte Biosciences presently has a consensus target price of $71.67, suggesting a potential downside of 6.84%. PDS Biotechnology has a consensus target price of $9.00, suggesting a potential upside of 4,145.28%. Given PDS Biotechnology’s stronger consensus rating and higher probable upside, analysts clearly believe PDS Biotechnology is more favorable than Forte Biosciences.

Institutional & Insider Ownership

77.6% of Forte Biosciences shares are held by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are held by institutional investors. 4.4% of Forte Biosciences shares are held by company insiders. Comparatively, 8.4% of PDS Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Forte Biosciences has a beta of 2.6, suggesting that its stock price is 160% more volatile than the S&P 500. Comparatively, PDS Biotechnology has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.

Summary

PDS Biotechnology beats Forte Biosciences on 7 of the 11 factors compared between the two stocks.

About Forte Biosciences

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.